论文部分内容阅读
分子靶向药物bevacizumab是针对血管内皮生长因子(VEGF)的重组人源化单克隆抗体,在多种恶性肿瘤的治疗中显示了临床效果。现就bevacizumab的作用机制及其在乳腺癌治疗中的临床研究进展作一综述。
The molecularly targeted drug bevacizumab is a recombinant humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF) and has demonstrated clinical efficacy in the treatment of a variety of malignancies. The mechanism of action of bevacizumab and its clinical progress in the treatment of breast cancer are reviewed.